Silence Therapeutics (NASDAQ:SLN – Get Free Report) and Absci (NASDAQ:ABSI – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.
Volatility & Risk
Silence Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Absci has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500.
Insider and Institutional Ownership
98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 52.0% of Absci shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Comparatively, 10.5% of Absci shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Silence Therapeutics | -8,943.86% | -106.94% | -47.99% |
| Absci | -7,756.38% | -61.71% | -54.52% |
Valuation and Earnings
This table compares Silence Therapeutics and Absci”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Silence Therapeutics | $560,000.00 | 1,202.05 | -$88.61 million | ($1.28) | -8.73 |
| Absci | $2.80 million | 596.96 | -$115.18 million | ($0.80) | -12.17 |
Silence Therapeutics has higher earnings, but lower revenue than Absci. Absci is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Silence Therapeutics and Absci, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Silence Therapeutics | 1 | 0 | 4 | 1 | 2.83 |
| Absci | 1 | 0 | 9 | 0 | 2.80 |
Silence Therapeutics currently has a consensus target price of $53.50, indicating a potential upside of 378.53%. Absci has a consensus target price of $13.71, indicating a potential upside of 40.80%. Given Silence Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Silence Therapeutics is more favorable than Absci.
Summary
Silence Therapeutics beats Absci on 8 of the 15 factors compared between the two stocks.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
About Absci
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
